MedTrace Logo

Urothelial Tumor Risk Genes Detection With Genetron Uro V1 and LC-WGS

NCT04994197 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 970

Last updated 2024-01-10

No results posted yet for this study

Summary

Genetron Uro V1 perform mutation detection of 17 genes and methylation detection of 1 gene by using urine samples and tumor tissue samples. It is a urine liquid biopsy method that has a great supplementary effect on the existing clinical differential diagnosis technology. The main aim of this study is to compare the test results of Genetron Uro V1 with the standard clinical diagnosis results, and analyze the performance of Genetron Uro V1 in the diagnosis and recurrence diagnosis of urothelial carcinoma.

Conditions

Interventions

OTHER

Observational study only - no intervention

Observational study only - no intervention

Sponsors & Collaborators

  • Hangzhou Genetron Medical Laboratory Co., Ltd.

    collaborator UNKNOWN

  • Ruijin Hospital

    lead OTHER

Principal Investigators

  • Danfeng Xu · Ruijin Hospital

  • Yiming Liang · Hangzhou Genetron Medical Laboratory Co., Ltd.

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-04-01
Primary Completion
2024-02-29
Completion
2024-08-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04994197 on ClinicalTrials.gov